MCID: BSL007
MIFTS: 64

Basal Cell Carcinoma

Categories: Cancer diseases, Skin diseases, Genetic diseases, Respiratory diseases, Rare diseases

Aliases & Classifications for Basal Cell Carcinoma

MalaCards integrated aliases for Basal Cell Carcinoma:

Name: Basal Cell Carcinoma 12 76 37 29 6 15 73
Basal Cell Cancer 12 55 73
Malignant Basal Cell Tumor 12 73
Basal Cell Neoplasm 12 73
Experimental Organism Basal Cell Carcinoma 73
Nodulo-Ulcerative Basal Cell Carcinoma 73
Malignant Basal Cell Neoplasm 12
Basal Cell Carcinoma of Skin 12
Epithelioma Basal Cell 12
Carcinoma, Basal Cell 44
Neoplasms, Basal Cell 44
Carcinoma Basal Cell 55
Basal Cell Tumor 12
Rodent Ulcer 12

Classifications:



Summaries for Basal Cell Carcinoma

Disease Ontology : 12 A skin carcinoma affecting basal cells.

MalaCards based summary : Basal Cell Carcinoma, also known as basal cell cancer, is related to basal cell carcinoma 1 and basal cell carcinoma, multiple. An important gene associated with Basal Cell Carcinoma is SMO (Smoothened, Frizzled Class Receptor), and among its related pathways/superpathways are Basal cell carcinoma and G-Beta Gamma Signaling. The drugs Erivedge and Intron A have been mentioned in the context of this disorder. Affiliated tissues include skin, breast and lung, and related phenotypes are growth/size/body region and digestive/alimentary

Wikipedia : 76 Basal-cell carcinoma (BCC), also known as basal-cell cancer, is the most common type of skin cancer. It... more...

Related Diseases for Basal Cell Carcinoma

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Cell Type Cancer
Cell Type Benign Neoplasm Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Basal Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 294)
# Related Disease Score Top Affiliating Genes
1 basal cell carcinoma 1 35.7 BCC1 PTCH1
2 basal cell carcinoma, multiple 35.2 PTCH1 PTCH2 SMO
3 basal cell nevus syndrome 34.7 GLI1 GLI2 PTCH1 PTCH2 SHH SMO
4 keratocystic odontogenic tumor 31.8 GLI1 PTCH1 SHH SMO SUFU TP53
5 ameloblastoma 31.3 GLI1 PTCH1 SMO
6 medulloblastoma 30.7 CDKN2B-AS1 CTNNB1 GLI1 GLI2 PTCH1 PTCH2
7 skin melanoma 30.5 CTNNB1 MC1R TP53
8 spiradenoma 30.1 CYLD TP53
9 basal cell carcinoma 7 12.4
10 nodular basal cell carcinoma 12.3
11 superficial basal cell carcinoma 12.3
12 basal cell carcinoma, infundibulocystic 12.3
13 morpheaform basal cell carcinoma 12.3
14 pigmented basal cell carcinoma 12.3
15 adenoid basal cell carcinoma 12.2
16 cystic basal cell carcinoma 12.2
17 clear cell basal cell carcinoma 12.2
18 sarcomatoid basal cell carcinoma 12.2
19 vulva basal cell carcinoma 12.2
20 infiltrative basal cell carcinoma 12.2
21 vulvar basal cell carcinoma 12.2
22 metatypical basal cell carcinoma 12.2
23 scrotum basal cell carcinoma 12.2
24 micronodular basal cell carcinoma 12.2
25 penis basal cell carcinoma 12.2
26 fibroepithelial basal cell carcinoma 12.2
27 bazex syndrome 12.1
28 basal cell carcinoma 2 12.1
29 basal cell carcinoma 3 12.1
30 basal cell carcinoma 4 12.1
31 basal cell carcinoma 5 12.1
32 basal cell carcinoma 6 12.1
33 anal margin basal cell carcinoma 12.1
34 external ear basal cell carcinoma 12.1
35 follicular basal cell carcinoma 12.1
36 signet ring basal cell carcinoma 12.1
37 sebaceous basal cell carcinoma 12.0
38 rombo syndrome 11.9
39 brooke-spiegler syndrome 11.3
40 multiple familial trichoepithelioma 11.3
41 calcifying epithelial odontogenic tumor 11.2 GLI2 PTCH1 TP53
42 adamantinoid basal cell epithelioma 11.1
43 septopreoptic holoprosencephaly 11.1 GLI2 PTCH1 SHH
44 midline interhemispheric variant of holoprosencephaly 11.1 GLI2 PTCH1 SHH
45 cerebellum cancer 11.1 SHH SUFU TP53
46 alobar holoprosencephaly 11.1 GLI2 PTCH1 SHH
47 trichoepithelioma, multiple familial, 1 11.1
48 microform holoprosencephaly 11.1 GLI2 PTCH1 SHH SUFU
49 lobar holoprosencephaly 11.1 GLI2 PTCH1 SHH
50 pallister-hall syndrome 11.1 GLI1 GLI2 SHH

Graphical network of the top 20 diseases related to Basal Cell Carcinoma:



Diseases related to Basal Cell Carcinoma

Symptoms & Phenotypes for Basal Cell Carcinoma

MGI Mouse Phenotypes related to Basal Cell Carcinoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.22 CTNNB1 CYLD GLI1 GLI2 MC1R PALB2
2 digestive/alimentary MP:0005381 10.21 GLI2 PTCH1 PTCH2 SHH SMO SUFU
3 craniofacial MP:0005382 10.18 CTNNB1 GLI1 GLI2 MC1R PTCH1 SHH
4 embryo MP:0005380 10.15 CTNNB1 GLI1 GLI2 PALB2 PTCH1 SHH
5 limbs/digits/tail MP:0005371 10.14 CTNNB1 CYLD GLI1 GLI2 MC1R PALB2
6 integument MP:0010771 10.13 CTNNB1 CYLD GLI2 MC1R PALB2 PTCH1
7 neoplasm MP:0002006 10.02 CTNNB1 CYLD GLI1 MC1R PALB2 PTCH1
8 hearing/vestibular/ear MP:0005377 10 CTNNB1 GLI2 MC1R PTCH1 SHH SMO
9 muscle MP:0005369 9.91 PTCH2 SHH SMO TP53 CTNNB1 GLI2
10 no phenotypic analysis MP:0003012 9.86 SHH SUFU TP53 CTNNB1 GLI1 GLI2
11 normal MP:0002873 9.85 CTNNB1 CYLD GLI1 GLI2 PTCH1 PTCH2
12 pigmentation MP:0001186 9.35 CTNNB1 MC1R PTCH1 SUFU TP53
13 respiratory system MP:0005388 9.28 GLI2 PTCH1 SHH CTNNB1 CYLD GLI1

Drugs & Therapeutics for Basal Cell Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Erivedge 18 49 VISMODEGIB Genentech January 2012
2
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
3
Odomzo 18 49 SONIDEGIB PHOSPHATE Novartis Jul-15

Drugs for Basal Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 281)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 106-60-5 137
2
Imiquimod Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99011-02-6 57469
3
Everolimus Approved Phase 4,Phase 1 159351-69-6 6442177
4
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 22916-47-8 4189
5
Sirolimus Approved, Investigational Phase 4,Phase 1 53123-88-9 5284616 6436030 46835353
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
7
Azathioprine Approved Phase 4 446-86-6 2265
8
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
9
Mycophenolic acid Approved Phase 4 24280-93-1 446541
10 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
11 Methyl 5-aminolevulinate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Photosensitizing Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
13 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Interferon Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 interferons Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
16 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
17 Antiviral Agents Phase 4,Phase 2,Phase 1,Not Applicable
18 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
19 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
20 Antirheumatic Agents Phase 4,Phase 2,Phase 3,Not Applicable
21 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
22 Interferon-alpha Phase 4
23 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
24 Calcineurin Inhibitors Phase 4
25 Cyclosporins Phase 4
26
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 50-18-0, 6055-19-2 2907
27
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
28
Zinc Approved, Investigational Phase 3 7440-66-6 23994
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
30
Fluconazole Approved, Investigational Phase 2, Phase 3 86386-73-4 3365
31
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
32
Megestrol acetate Approved, Investigational, Vet_approved Phase 3 595-33-5 11683
33
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
34
Histamine Approved, Investigational Phase 3,Not Applicable 75614-87-8, 51-45-6 774
35
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
36
Anastrozole Approved, Investigational Phase 3,Phase 2 120511-73-1 2187
37
Tamoxifen Approved Phase 3 10540-29-1 2733526
38
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 1 154361-50-9 60953
39
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 114977-28-5 148124
40
Epirubicin Approved Phase 2, Phase 3,Phase 1 56420-45-2 41867
41
Paclitaxel Approved, Vet_approved Phase 2, Phase 3,Phase 3 33069-62-4 36314
42
Trastuzumab Approved, Investigational Phase 2, Phase 3,Phase 3,Early Phase 1 180288-69-1 9903
43
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
44
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
45
Triamcinolone Approved, Vet_approved Phase 3,Phase 2 124-94-7 31307
46
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
47
Verteporfin Approved, Investigational Phase 3 129497-78-5
48
Ornithine Approved, Nutraceutical Phase 3,Phase 2 70-26-8, 3184-13-2 6262
49
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1,Phase 2 302-79-4 5538 444795
50
Beta carotene Approved, Nutraceutical Phase 3 7235-40-7

Interventional clinical trials:

(show top 50) (show all 317)
# Name Status NCT ID Phase Drugs
1 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
2 Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma Unknown status NCT00803907 Phase 4 Imiquimod 5% cream
3 Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage Completed NCT00314756 Phase 4 imiquimod
4 Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC) Completed NCT00581425 Phase 4
5 Safety and Efficacy Study of Imiquimod 5% Cream Applied 3x Per Week for 8 or 12 Weeks in Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
6 Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
7 VISmodegib for ORbital and Periocular Basal Cell Carcinoma Recruiting NCT02436408 Phase 4 Vismodegib
8 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
9 Periocular Basal Cell Carcinoma (BCC): Permanent vs. Frozen Section Pathological Control Unknown status NCT00663650 Phase 3
10 Open-label Study to Evaluate Clearance of Superficial Basal Cell Carcinoma After Use of Imiquimod 5% Cream Completed NCT00189306 Phase 3 Imiquimod 5% cream
11 A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma Completed NCT00189241 Phase 3 imiquimod
12 Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma Completed NCT00472108 Phase 3
13 Metvix PDT Versus Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma Completed NCT00469417 Phase 3
14 A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence Completed NCT00129519 Phase 3 Imiquimod 5% cream
15 Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma Completed NCT01212549 Phase 3
16 Metvix PDT in Patients With "High Risk" Basal Cell Carcinoma Completed NCT00473343 Phase 3
17 Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer Completed NCT00066872 Phase 3 imiquimod
18 Fractional CO2 Laser Assisted Photodynamic Therapy Completed NCT01260987 Phase 2, Phase 3 Conventional photodynamic therapy;Fractional CO2 laser assisted PDT
19 PDT With Metvix 160 mg/g Cream Versus PDT With Placebo Cream in Patients With Primary Nodular Basal Call Carcinoma Completed NCT00472043 Phase 3
20 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
21 Aldara for the Treatment of Large and/or Multiple sBCC Completed NCT00189280 Phase 3 Imiquimod
22 Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer Completed NCT00005884 Phase 3 eflornithine
23 Determine the Efficacy of Topical Tretinoin Cream for the Prevention of Nonmelanoma Skin Cancer Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
24 Primary Prevention Trial of the Health Effects of Antioxidant Vitamins and Minerals. Completed NCT00272428 Phase 3
25 Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer Completed NCT00374322 Phase 3 lapatinib
26 PDT With Metvix® 160 mg/g Cream in Organ Transplant Recipients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
27 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
28 Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer Completed NCT00090337 Phase 3
29 Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00002533 Phase 2, Phase 3 fluconazole
30 Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer Completed NCT00017511 Phase 3 cevimeline hydrochloride
31 Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer Completed NCT00006799 Phase 3 megestrol acetate
32 Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
33 Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Completed NCT01362140 Phase 3 Darbepoetin alfa;Placebo
34 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3 anastrozole;tamoxifen citrate
35 Radiotherapy or Imiquimod in Complex Lentigo Maligna Recruiting NCT02394132 Phase 3 Imiquimod
36 A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin Recruiting NCT03085368 Phase 2, Phase 3 lapatinib/herceptin
37 Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Recruiting NCT02488967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Paclitaxel
38 Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma Active, not recruiting NCT02242929 Phase 3 Imiquimod 5% cream with prior curettage
39 Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy Active, not recruiting NCT02144077 Phase 3 BF-200 ALA;methyl-aminolevulinate
40 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
41 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
42 Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). Not yet recruiting NCT03573401 Phase 3
43 Two Studies to Determine if Verteporfin PDT is Effective & Safe in Treating Multiple Basal Cell Carcinoma of the Skin. Terminated NCT00049959 Phase 3 verteporfin PDT
44 Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ Transplanted Patients Terminated NCT01532453 Phase 3
45 Efficacy, Safety and Tolerability of Topically Applied LDE225 Cream (Hedgehog Pathway Inhibitor) in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome (NBCCS) Withdrawn NCT03070691 Phase 2, Phase 3 LDE225B;Vehicle
46 Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
47 Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight Unknown status NCT01349361 Phase 2
48 Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Skin Cancer Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
49 Early Detection of Skin Cancer With Sensor Technology Unknown status NCT02668614 Phase 2
50 Low Fat Diet to Prevent Disease Progression in Patients With Skin Cancer Unknown status NCT00003097 Phase 2

Search NIH Clinical Center for Basal Cell Carcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: carcinoma, basal cell

Genetic Tests for Basal Cell Carcinoma

Genetic tests related to Basal Cell Carcinoma:

# Genetic test Affiliating Genes
1 Basal Cell Carcinoma 29

Anatomical Context for Basal Cell Carcinoma

MalaCards organs/tissues related to Basal Cell Carcinoma:

41
Skin, Breast, Lung, Brain, Kidney, Liver, Bone

Publications for Basal Cell Carcinoma

Articles related to Basal Cell Carcinoma:

(show top 50) (show all 1899)
# Title Authors Year
1
Dermoscopic and reflectance confocal microscopy features of two cases of vulvar basal cell carcinoma. ( 29445582 )
2018
2
Novel PTCH1 Gene Mutation in Nevoid Basal Cell Carcinoma Syndrome. ( 29381605 )
2018
3
BRCA1-Associated Protein-1 Tumor Predisposition Syndrome in a Patient With Numerous Basal Cell Carcinomas. ( 29757857 )
2018
4
Basal cell carcinoma and malignant melanoma cutaneous collision tumor. ( 29904313 )
2018
5
Collagen disruption as a marker for basal cell carcinoma in presurgical margin detection. ( 29900551 )
2018
6
Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. ( 29939876 )
2018
7
Genital basal cell carcinoma, a different pathogenesis from sun-exposed basal cell carcinoma? A case-control study of 30 cases. ( 29920730 )
2018
8
Cryosurgery + 5% 5-Fluorouracil for Treatment of Superficial Basal Cell Carcinoma and Bowen's Disease [Formula: see text]. ( 29457484 )
2018
9
Infiltrative basal cell carcinoma mimicking tinea corporis. ( 29634889 )
2018
10
Comparing Topical Treatments forA Basal Cell Carcinoma. ( 29395168 )
2018
11
Frontal axial pattern flap combined with hard palate mucosa transplant in the reconstruction of midfacial defects after the excision of huge basal cell carcinoma. ( 29958532 )
2018
12
Accuracy of dermoscopic criteria for the differentiation between superficial basal cell carcinoma and Bowen's disease. ( 29633377 )
2018
13
Plaque-Type Syringoma Coexisting With Basal Cell Carcinoma. ( 29419541 )
2018
14
Comparison of long term cosmetic outcomes for different treatments of superficial basal cell carcinoma. ( 29753062 )
2018
15
Excision of nodular basal cell carcinoma involving the lower eyelid tarsal skin using a grey line-splitting, posterior lamella-sparing technique. ( 29461902 )
2018
16
Basal cell carcinoma in a 17 year-old organ transplant recipient. ( 29962023 )
2018
17
PTCH1 Germline Mutations and the Basaloid Follicular Hamartoma Values in the Tumor Spectrum of Basal Cell Carcinoma Syndrome (NBCCS). ( 29277811 )
2018
18
Functional Reconstruction with Latissimus Dorsi Flap following Resection of an Extensive Basal Cell Carcinoma in the Shoulder Region: A Case Report. ( 29896564 )
2018
19
Quantitative Analysis on Ex Vivo Nonlinear Microscopy Images of Basal Cell Carcinoma Samples in Comparison to Healthy Skin. ( 29981012 )
2018
20
Features Causing Confusion between Basal Cell Carcinoma and Squamous Cell Carcinoma in Clinical Diagnosis. ( 29386834 )
2018
21
Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies. ( 29399405 )
2018
22
Expression profile of the amino acid transporters SLC7A5, SLC7A7, SLC7A8 and the enzyme TDO2 in basal cell carcinoma. ( 29938775 )
2018
23
Optical coherence tomography image processing for in vivo 3-dimensional visualization of basal cell carcinoma. ( 29368446 )
2018
24
Needs and preferences of patients regarding basal cell carcinoma and cutaneous squamous cell carcinoma care: a qualitative focus group study. ( 29927480 )
2018
25
The curious case of a forehead metatypical basal cell carcinoma. ( 29940648 )
2018
26
9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient. ( 29057423 )
2018
27
A randomized, multi-national, non-inferiority, phase III trial to evaluate the safety and efficacy of BF-200 ALA gel versus MAL cream in the treatment of non-aggressive basal cell carcinoma with photodynamic therapy (PDT). ( 29432644 )
2018
28
Erythrocyte Membrane Unsaturated (Mono and Poly) Fatty Acids Profile in Newly Diagnosed Basal Cell Carcinoma Patients. ( 29423386 )
2018
29
Nodular basal cell carcinoma of the face successfully treated with ingenol mebutate 0.015% gel. ( 29785331 )
2018
30
Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib. ( 29387745 )
2018
31
Correction to:A Cancer associated fibroblasts (CAFs) are activated in cutaneous basal cell carcinoma and in the peritumoural skin. ( 29382305 )
2018
32
Application of in vivo reflectance confocal microscopy (RCM) and ex vivo fluorescence confocal microscopy (FCM) in most common subtypes of Basal Cell Carcinoma and correlation with histopathology. ( 29405259 )
2018
33
Laser-assisted photodynamic therapy for superficial basal cell carcinoma and Bowen's Disease: a randomised intra-patient comparison between a continuous and a fractional ablative CO<sub>2</sub> laser mode. ( 29633367 )
2018
34
Tumor Architecture and Notch Signaling Modulate Drug Response in Basal Cell Carcinoma. ( 29395868 )
2018
35
Evaluation of the appropriate surgical margin for pigmented basal cell carcinoma according to the risk factors for recurrence: a single-institute retrospective study in Japan. ( 29729096 )
2018
36
Sonidegib for basal cell carcinoma. ( 29922006 )
2018
37
Basal Cell Carcinoma of the Buttock. ( 29911527 )
2018
38
Solitary plantar basal cell carcinoma. ( 29924227 )
2018
39
Basal cell carcinoma of the scrotum: an important but easily overlooked entity. ( 29377295 )
2018
40
Angiosarcoma following treatment of basal cell carcinoma: a report of two cases. ( 29345300 )
2018
41
CD10, TDAG51, CK20, AR, INSM1, and Nestin Expression in the Differential Diagnosis of Trichoblastoma and Basal Cell Carcinoma. ( 29938548 )
2018
42
Basal Cell Carcinoma Mimicking Desmoplastic Trichoepithelioma: A Case with Correlation of Dermoscopy and Histology. ( 29928202 )
2018
43
Low recurrence rate of head and neck basal cell carcinoma treated with Mohs micrographic surgery: A retrospective study of 1021 cases. ( 29953746 )
2018
44
Diagnostic Accuracy of Immunohistochemical Markers in Differentiation between Basal Cell Carcinoma and Trichoepithelioma in small Biopsy Specimens. ( 29917261 )
2018
45
An expanded study of long-pulsed 1064a88nm Nd:YAG laser treatment of basal cell carcinoma. ( 29436720 )
2018
46
Basal cell carcinoma induced by therapeutic radiation for tinea capitis-clinicopathological study. ( 29464746 )
2018
47
Ophthalmomyiasis in a case of basal cell carcinoma of eyelid. ( 29866693 )
2018
48
Is a single day patient friendly methyl aminolevulinate photodynamic therapy illumination scheme for superficial basal cell carcinoma feasible? A randomized multicenter pilot trial. ( 29862877 )
2018
49
A Novel PTCH1 Frameshift Mutation Leading to Nevoid Basal Cell Carcinoma Syndrome. ( 29544218 )
2018
50
Reevaluating Mohs Surgery Appropriate Use Criteria for Primary Superficial Basal Cell Carcinoma. ( 29516099 )
2018

Variations for Basal Cell Carcinoma

ClinVar genetic disease variations for Basal Cell Carcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 PALB2 NM_024675.3(PALB2): c.1451T> A (p.Leu484Ter) single nucleotide variant Pathogenic/Likely pathogenic rs786203714 GRCh37 Chromosome 16, 23646416: 23646416
2 PALB2 NM_024675.3(PALB2): c.1451T> A (p.Leu484Ter) single nucleotide variant Pathogenic/Likely pathogenic rs786203714 GRCh38 Chromosome 16, 23635095: 23635095
3 SMO NM_005631.4(SMO): c.1417G> C (p.Asp473His) single nucleotide variant Pathogenic rs17710891 GRCh37 Chromosome 7, 128849189: 128849189
4 SMO NM_005631.4(SMO): c.1417G> C (p.Asp473His) single nucleotide variant Pathogenic rs17710891 GRCh38 Chromosome 7, 129209348: 129209348

Cosmic variations for Basal Cell Carcinoma:

9
(show top 50) (show all 687)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6926860 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.5825G>A p.G1942E 16:72796857-72796857 20
2 COSM6926861 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1655C>T p.S552F 16:72958491-72958491 20
3 COSM6969201 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.11050G>A p.D3684N 16:72787226-72787226 20
4 COSM6953811 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1991C>T p.S664F 16:72958155-72958155 20
5 COSM6926862 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1261G>A p.G421R 16:72958885-72958885 20
6 COSM6936924 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.10847C>T p.S3616F 16:72787429-72787429 20
7 COSM3691166 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.2084C>T p.P695L 16:72958062-72958062 20
8 COSM212945 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 20
9 COSM6953809 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 20
10 COSM6936922 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 20
11 COSM6926855 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 20
12 COSM6912933 TRAF7 skin,NS,carcinoma,basal cell carcinoma c.1802C>T p.T601I 16:2176104-2176104 20
13 COSM6949578 TP63 skin,NS,carcinoma,basal cell carcinoma c.1922C>T p.A641V 3:189894381-189894381 20
14 COSM44071 TP53 skin,NS,carcinoma,basal cell carcinoma c.955A>G p.K319E 17:7673573-7673573 20
15 COSM44097 TP53 skin,NS,carcinoma,basal cell carcinoma c.530C>T p.P177L 17:7675082-7675082 20
16 COSM44096 TP53 skin,NS,carcinoma,basal cell carcinoma c.748C>G p.P250A 17:7674215-7674215 20
17 COSM10728 TP53 skin,NS,carcinoma,basal cell carcinoma c.839G>A p.R280K 17:7673781-7673781 20
18 COSM45169 TP53 skin,NS,carcinoma,basal cell carcinoma c.326T>C p.F109S 17:7676043-7676043 20
19 COSM43842 TP53 skin,NS,carcinoma,basal cell carcinoma c.770T>C p.L257P 17:7674193-7674193 20
20 COSM43695 TP53 skin,NS,carcinoma,basal cell carcinoma c.748C>T p.P250S 17:7674215-7674215 20
21 COSM10988 TP53 skin,NS,carcinoma,basal cell carcinoma c.772G>A p.E258K 17:7674191-7674191 20
22 COSM45739 TP53 skin,NS,carcinoma,basal cell carcinoma c.677G>C p.G226A 17:7674286-7674286 20
23 COSM44295 TP53 skin,NS,carcinoma,basal cell carcinoma c.993+1G>A p.? 17:7673534-7673534 20
24 COSM43778 TP53 skin,NS,carcinoma,basal cell carcinoma c.713G>T p.C238F 17:7674250-7674250 20
25 COSM10939 TP53 skin,NS,carcinoma,basal cell carcinoma c.832C>T p.P278S 17:7673788-7673788 20
26 COSM10650 TP53 skin,NS,carcinoma,basal cell carcinoma c.529C>T p.P177S 17:7675083-7675083 20
27 COSM43665 TP53 skin,NS,carcinoma,basal cell carcinoma c.746G>C p.R249T 17:7674217-7674217 20
28 COSM10662 TP53 skin,NS,carcinoma,basal cell carcinoma c.743G>A p.R248Q 17:7674220-7674220 20
29 COSM45774 TP53 skin,NS,carcinoma,basal cell carcinoma c.899C>G p.P300R 17:7673721-7673721 20
30 COSM10749 TP53 skin,NS,carcinoma,basal cell carcinoma c.830G>T p.C277F 17:7673790-7673790 20
31 COSM11449 TP53 skin,NS,carcinoma,basal cell carcinoma c.388C>T p.L130F 17:7675224-7675224 20
32 COSM10660 TP53 skin,NS,carcinoma,basal cell carcinoma c.818G>A p.R273H 17:7673802-7673802 20
33 COSM10771 TP53 skin,NS,carcinoma,basal cell carcinoma c.749C>T p.P250L 17:7674214-7674214 20
34 COSM44068 TP53 skin,NS,carcinoma,basal cell carcinoma c.532C>A p.H178N 17:7675080-7675080 20
35 COSM11152 TP53 skin,NS,carcinoma,basal cell carcinoma c.700T>C p.Y234H 17:7674263-7674263 20
36 COSM43582 TP53 skin,NS,carcinoma,basal cell carcinoma c.454C>T p.P152S 17:7675158-7675158 20
37 COSM10768 TP53 skin,NS,carcinoma,basal cell carcinoma c.535C>T p.H179Y 17:7675077-7675077 20
38 COSM45834 TP53 skin,NS,carcinoma,basal cell carcinoma c.409C>A p.L137M 17:7675203-7675203 20
39 COSM10905 TP53 skin,NS,carcinoma,basal cell carcinoma c.451C>T p.P151S 17:7675161-7675161 20
40 COSM10654 TP53 skin,NS,carcinoma,basal cell carcinoma c.637C>T p.R213* 17:7674894-7674894 20
41 COSM6932 TP53 skin,NS,carcinoma,basal cell carcinoma c.733G>A p.G245S 17:7674230-7674230 20
42 COSM10648 TP53 skin,NS,carcinoma,basal cell carcinoma c.524G>A p.R175H 17:7675088-7675088 20
43 COSM45424 TP53 skin,NS,carcinoma,basal cell carcinoma c.781A>T p.S261C 17:7674182-7674182 20
44 COSM10812 TP53 skin,NS,carcinoma,basal cell carcinoma c.722C>T p.S241F 17:7674241-7674241 20
45 COSM10656 TP53 skin,NS,carcinoma,basal cell carcinoma c.742C>T p.R248W 17:7674221-7674221 20
46 COSM10659 TP53 skin,NS,carcinoma,basal cell carcinoma c.817C>T p.R273C 17:7673803-7673803 20
47 COSM10794 TP53 skin,NS,carcinoma,basal cell carcinoma c.796G>A p.G266R 17:7673824-7673824 20
48 COSM44552 TP53 skin,NS,carcinoma,basal cell carcinoma c.509C>T p.T170M 17:7675103-7675103 20
49 COSM10704 TP53 skin,NS,carcinoma,basal cell carcinoma c.844C>T p.R282W 17:7673776-7673776 20
50 COSM10726 TP53 skin,NS,carcinoma,basal cell carcinoma c.856G>A p.E286K 17:7673764-7673764 20

Copy number variations for Basal Cell Carcinoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 256908 9 98205264 98279247 Mutation PTCH Basal cell carcinoma

Expression for Basal Cell Carcinoma

Search GEO for disease gene expression data for Basal Cell Carcinoma.

Pathways for Basal Cell Carcinoma

Pathways related to Basal Cell Carcinoma according to KEGG:

37
# Name Kegg Source Accession
1 Basal cell carcinoma hsa05217

Pathways related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.87 CTNNB1 GLI1 GLI2 PTCH1 PTCH2 SMO
2 12.7 CTNNB1 GLI1 GLI2 PTCH1 PTCH2 SHH
3
Show member pathways
12.42 GLI1 GLI2 PTCH1 SHH SMO SUFU
4
Show member pathways
12.21 PTCH1 PTCH2 SHH SMO
5 12.13 CTNNB1 PTCH1 SHH SMO TP53
6 11.82 CTNNB1 CYLD GLI1 GLI2 PTCH1 PTCH2
7
Show member pathways
11.81 GLI1 GLI2 PTCH1 PTCH2 SHH SMO
8
Show member pathways
11.46 CTNNB1 GLI1 GLI2 PTCH1 PTCH2 SHH
9 11.36 GLI1 GLI2 PTCH1 SHH SMO
10
Show member pathways
11.17 GLI2 PTCH1 PTCH2 SHH SMO
11 11.13 GLI1 GLI2 SHH
12 10.4 PTCH1 SHH

GO Terms for Basal Cell Carcinoma

Cellular components related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cilium GO:0005929 9.55 GLI1 GLI2 PTCH1 SMO SUFU
2 ciliary base GO:0097546 9.13 GLI1 GLI2 SUFU
3 ciliary tip GO:0097542 9.02 CYLD GLI1 GLI2 SMO SUFU

Biological processes related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Name GO ID Score Top Affiliating Genes
1 in utero embryonic development GO:0001701 9.97 CTNNB1 GLI2 PALB2 PTCH1 SMO
2 kidney development GO:0001822 9.92 CTNNB1 GLI2 SHH
3 osteoblast differentiation GO:0001649 9.92 GLI1 GLI2 SMO
4 lung development GO:0030324 9.92 CTNNB1 GLI1 GLI2 SHH
5 anterior/posterior pattern specification GO:0009952 9.91 GLI2 SHH SMO
6 canonical Wnt signaling pathway GO:0060070 9.9 CTNNB1 GLI1 SHH SMO
7 determination of left/right symmetry GO:0007368 9.89 SHH SMO SUFU
8 vasculogenesis GO:0001570 9.88 CTNNB1 SHH SMO
9 embryonic digit morphogenesis GO:0042733 9.88 CTNNB1 GLI2 SHH
10 heart looping GO:0001947 9.88 SHH SMO SUFU
11 branching involved in ureteric bud morphogenesis GO:0001658 9.87 CTNNB1 PTCH1 SHH
12 positive regulation of smoothened signaling pathway GO:0045880 9.83 GLI1 SHH SMO
13 developmental growth GO:0048589 9.83 GLI2 SHH SMO
14 odontogenesis of dentin-containing tooth GO:0042475 9.83 CTNNB1 GLI2 SHH SMO
15 positive regulation of mesenchymal cell proliferation GO:0002053 9.82 CTNNB1 SHH SMO
16 hair follicle morphogenesis GO:0031069 9.81 CTNNB1 SHH SMO
17 pattern specification process GO:0007389 9.81 GLI2 PTCH1 SHH SMO
18 negative regulation of smoothened signaling pathway GO:0045879 9.8 PTCH1 PTCH2 SUFU
19 skin development GO:0043588 9.8 CTNNB1 PTCH2 SHH SUFU
20 proximal/distal pattern formation GO:0009954 9.79 CTNNB1 GLI1 GLI2
21 regulation of smoothened signaling pathway GO:0008589 9.79 GLI1 GLI2 PTCH1
22 hindbrain development GO:0030902 9.78 CTNNB1 GLI2 SHH
23 embryonic organ development GO:0048568 9.78 PALB2 PTCH1 SHH SMO
24 spinal cord motor neuron differentiation GO:0021522 9.77 GLI2 PTCH1 SHH
25 smoothened signaling pathway GO:0007224 9.77 GLI1 GLI2 PTCH1 SHH SMO
26 positive regulation of neuroblast proliferation GO:0002052 9.76 CTNNB1 SHH SMO
27 male genitalia development GO:0030539 9.75 CTNNB1 SHH
28 cell fate specification GO:0001708 9.75 CTNNB1 SHH SMO
29 osteoblast development GO:0002076 9.74 GLI2 SHH
30 negative regulation of chondrocyte differentiation GO:0032331 9.74 CTNNB1 GLI2
31 epithelial tube branching involved in lung morphogenesis GO:0060441 9.74 CTNNB1 SHH
32 regulation of osteoblast differentiation GO:0045667 9.73 CTNNB1 GLI1
33 digestive tract morphogenesis GO:0048546 9.73 GLI1 SHH
34 ectoderm development GO:0007398 9.73 CTNNB1 SHH
35 mammary gland epithelial cell differentiation GO:0060644 9.73 PTCH1 SMO
36 thalamus development GO:0021794 9.73 SHH SMO
37 cell fate determination GO:0001709 9.73 CTNNB1 PTCH1 PTCH2
38 cellular response to cholesterol GO:0071397 9.72 PTCH1 SMO
39 positive regulation of T cell differentiation in thymus GO:0033089 9.72 GLI2 SHH
40 positive regulation of skeletal muscle tissue development GO:0048643 9.72 CTNNB1 SHH
41 embryonic foregut morphogenesis GO:0048617 9.71 CTNNB1 SHH
42 positive regulation of epidermal cell differentiation GO:0045606 9.71 PTCH1 PTCH2
43 lung-associated mesenchyme development GO:0060484 9.71 CTNNB1 SHH
44 somite development GO:0061053 9.71 PTCH1 SHH SMO
45 renal system development GO:0072001 9.71 CTNNB1 PTCH1 SHH SMO
46 smoothened signaling pathway involved in dorsal/ventral neural tube patterning GO:0060831 9.7 GLI2 PTCH1
47 mammary gland duct morphogenesis GO:0060603 9.7 GLI2 PTCH1
48 hindgut morphogenesis GO:0007442 9.69 GLI2 SHH
49 epithelial-mesenchymal cell signaling GO:0060684 9.69 SHH SMO
50 trachea morphogenesis GO:0060439 9.68 CTNNB1 SHH

Molecular functions related to Basal Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hedgehog receptor activity GO:0008158 9.26 PTCH1 PTCH2
2 smoothened binding GO:0005119 9.16 PTCH1 PTCH2
3 hedgehog family protein binding GO:0097108 8.96 PTCH1 PTCH2
4 patched binding GO:0005113 8.8 PTCH1 SHH SMO

Sources for Basal Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....